(Hypertension. 1996;28:622-626.)
© 1996 American Heart Association, Inc.
Articles |
the Genetic Physiology Unit, Department of Medicine, University of Melbourne (Victoria, Australia), Austin Hospital.
Angiotensin-converting enzyme inhibitors reduce blood pressure and cardiac mass but may also have a direct effect on myocardial growth. To test this hypothesis, we studied the effects of perindopril on the weight of transplanted hearts in which the left ventricle does not pump blood. Hearts were transplanted between littermate 10-week-old male spontaneously hypertensive rats, and recipients were treated for 2 weeks with vehicle (n=10), perindopril (3 mg/kg per day) (n=9), perindopril (3 mg/kg per day) plus the selective bradykinin B2 receptor antagonist Hoe 140 (500 µg/kg per day) (n=13), or angiotensin II (200 ng/kg per minute) (n=12). Perindopril reduced blood pressure and native left ventricular weight and also caused a significant decrease in the weight of the transplanted left ventricle compared with controls. Hoe 140 did not significantly alter blood pressure or native left ventricular weight of perindopril-treated rats but caused a significant increase in the weight of the transplanted left ventricle compared with rats treated with perindopril alone. Angiotensin treatment resulted in a significant increase in blood pressure and native left ventricular weight but no significant change in the weight of the transplanted left ventricle. Blood pressure and left ventricular weight for native but not for transplanted hearts were positively correlated. Therefore, in the absence of mechanical load, the weight of the left ventricle of spontaneously hypertensive rats responds little to angiotensin II but can be reduced by angiotensin-converting enzyme inhibition. The effect of perindopril on transplanted hearts of spontaneously hypertensive rats appears to depend on bradykinin.
Key Words: angiotensin bradykinin hypertension, genetic hypertrophy transplantation
This article has been cited by other articles:
![]() |
S. Goland, L. S.C. Czer, R. M. Kass, R. J. Siegel, J. Mirocha, M. A. De Robertis, J. Lee, S. Raissi, W. Cheng, G. Fontana, et al. Use of Cardiac Allografts With Mild and Moderate Left Ventricular Hypertrophy Can Be Safely Used in Heart Transplantation to Expand the Donor Pool J. Am. Coll. Cardiol., March 25, 2008; 51(12): 1214 - 1220. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Higaki, M. Aoki, R. Morishita, I. Kida, Y. Taniyama, N. Tomita, K. Yamamoto, A. Moriguchi, Y. Kaneda, and T. Ogihara In Vivo Evidence of the Importance of Cardiac Angiotensin-Converting Enzyme in the Pathogenesis of Cardiac Hypertrophy Arterioscler. Thromb. Vasc. Biol., February 1, 2000; 20(2): 428 - 434. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.A. van Zwieten The influence of antihypertensive drug treatment on the prevention and regression of left ventricular hypertrophy Cardiovasc Res, January 1, 2000; 45(1): 82 - 91. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1996 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |